Retatrutide is a triple agonist, meaning it also hits GIP and glucagon receptors on top of GLP-1
The medication can be an effective and safe therapeutic option for managing obesity (BMI 30 or more) and overweight (BMI 27 or more)
Retatrutide is currently being studied for its ability to help: Reduce hunger Increase satiety Improve metabolic signaling Support fat loss through multiple hormonal pathways In a Phase 2 obesity trial published in The New England Journal of Medicine, retatrutide produced substantial weight loss over 48 weeks, with the highest-dose group showing mean weight loss of 24.2%
Whether youre navigating life after surgery or working toward weight loss without GLP-1 medications, the app helps silence food noise, reduce cravings, and simplify meal prep
O comunicado de maio no forneceu detalhes sobre eventos adversos, mas relatou que, na dose de 4mg, a descontinuao por efeitos adversos foi menor do que no placebo
In the periphery, GLP-1 is released from the gut in response to the presence of food nutrients